phytoestrogens and Adrenal-Cortex-Neoplasms

phytoestrogens has been researched along with Adrenal-Cortex-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for phytoestrogens and Adrenal-Cortex-Neoplasms

ArticleYear
Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells.
    Toxicology letters, 2010, Feb-15, Volume: 192, Issue:3

    Cytochrome P450c17 (CYP17) has been linked to various hormone-related diseases, including breast cancer, thus being a potential target for cancer chemoprevention. We studied the naturally occurring phytochemical enterolactone (ENL) and 13 VIOXX-related lactone derivatives (CRI-1 to CRI-13) for their effects on CYP17 activity and expression and on cell cycle status in the human H295R adrenocorticocarcinoma cell line. Of the tested compounds, only CRI-3, -7, -10 and -12 showed to be inhibitors of CYP17 activity in H295R cells. This inhibition was not due to decreased mRNA expression, but was apparently caused by post-translational modification of the CYP17 enzyme. The MAPK kinase (MEK) inhibitor PD98059 induced CYP17 activity by 24%, while co-incubation of the CRI-s with PD98059, reduced CYP17 activity even further than the reduction caused by the CRI-s alone. In addition, CRI-3, -7, -10 and -12 arrested the cell cycle in the G(2)/M phase. The structure-activity similarities of the CRI-s with known micro-tubule binding agents strongly suggest that cell cycle arrest is a result of interaction with tubulin. We conclude that the proposed cancer chemopreventive actions of ENL are not mediated through interaction with CYP17 or cell cycle status. Of the VIOXX-related lactone derivatives, CRI-7 could prove useful in the prevention of hormone-dependent cancers, such as breast cancer, since in vitro it shows low cytotoxicity, it is a potent inhibitor of CYP17 activity and strong inducer of cell cycle arrest.

    Topics: 4-Butyrolactone; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Cell Cycle; Cell Line, Tumor; Enzyme Induction; Flavonoids; Gene Expression; Humans; Lactones; Lignans; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Hormone-Dependent; Phytoestrogens; Protein Processing, Post-Translational; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Sulfones

2010
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity.
    Nutrition and cancer, 2010, Volume: 62, Issue:1

    Phytoestrogens (PEs) are naturally occurring plant components produced in a large range of plants. They can induce biologic responses in vertebrates by mimicking or modulating the action or production of endogenous hormones. This study examined mixtures of 12 food relevant PEs for effects on steroid hormone production, aromatase activity, estrogenic activity, and for interaction with the androgen receptor. The results show that a mixture of all tested PEs increased estradiol production and decreased testosterone production in H295R human adrenal corticocarcinoma cells, indicating an induced aromatase activity. Furthermore, exposure of the H295R cells to isoflavonoids caused a decrease in testosterone production, and various mixtures of PEs significantly stimulated MCF-7 human breast adenocarcinoma cell growth and induced aromatase activity in JEG-3 choriocarcinoma cells. The estrogenic effect in the MCF7 cells of the isoflavonoid mixture and coumestrol was supported by an observed increase in progesterone receptor protein expression as well as a decreased ERalpha expression. Overall, the results support that nutrition-relevant concentrations of PEs both alone and in mixtures possess various endocrine disrupting effects, all of which need to be considered when assessing the effects on human health.

    Topics: Adrenal Cortex Neoplasms; Aromatase; Breast Neoplasms; Cell Division; Cell Line, Tumor; Endocrine Disruptors; Estradiol; Estrogen Receptor alpha; Estrogens; Flavonoids; Food; Humans; Phytoestrogens; Plants, Edible; Receptors, Androgen; Receptors, Progesterone; Steroids; Testosterone

2010